Sep 11, 2024 7:00 am EDT DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
Sep 5, 2024 7:00 am EDT Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
Jul 30, 2024 7:00 am EDT Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
Jul 22, 2024 7:00 am EDT Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
Jul 15, 2024 7:00 am EDT Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
Jun 24, 2024 7:00 am EDT Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
Jun 20, 2024 7:00 am EDT Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
